New FDA Draft Guidance on Adcomm COI

03/21/2007 11:19 AM |

I am currently listening to an FDA stakeholder call on a new draft guidance for FDA advisory committee conflict of interest.

Rather than "in" or "out," the agency is suggesting three options:

(1) If an adcomm member has "some" conflicts, they can sit on the committee and participate in the meeting -- but cannot vote.

The FDA did not define what "some" means.

(2) If an adcomm member receives more than $50,000 compensation from a firm in front of an adcomm, they may not sit on the panal, participate in the debate, or vote.

It isn't clear (at least to me) in what period of time this money can be accrued (i.e., $50,000 in a calendar year, or in 12 months prior to the meeting, etc.).

(3) If a panel member has the "appearance" of a conflict they may be recused.

No definition of what "appearance" means. Perhaps this will be clarified in the actual draft guidance.

More as more develops.  Read More & Comment...

Medicare Advantage

03/21/2007 11:04 AM |

Want the facts and nothing but the facts on Medicare Advantage?

Of course you do, you're a drugwonk!

Have a look at this document:

Download file

CMPI is glad to have assisted in putting this fact sheet together.  Read More & Comment...

FDAMAmia

03/21/2007 10:04 AM |

Here's a link to the complete BioCentury feature, "Deconstructing FDAMA."

Download file

Many thanks to Bard Steve and BioCentury for the permission to share.  Read More & Comment...

The Road to Perdition

03/21/2007 09:11 AM |

Steve Usdin certainly has a way with words. Consider these pearls from the recent edition of BioCentury:

"Part of the lesson from FDAMA is that the road to regulatory perdition is paved with the best legislative intentions.

The fact is the Congress did not accompany its 1997 mandate for new treatments with any risks for FDA's failure to perform, and hasn't followed through with the resources to bring regulatory science into the 21st century.

Lawmakers also lost interest in the outcome, and now have turned their attention to raising political capital by easy grandstanding about safety.

The truth is that neither Vioxx nor anti-depressants, nor Ketek rise to the level of thalidomide. If it were so, then there would be a groundswell of calls to roll back FDAMA's mandate to being new treatments to patients who need them.

But even if there is no return to the pre-1997 era de jure, a de facto rollback is a real possibility unless Congress, regulators, patients and industry again are willing to do the hard work required to build the sophisticated systems to improve the risk-benefit calculus. This revived collaboration is necessary to make palatable the regulatory risk that everyone must accept if the new science is to make its way to the bedside."

We hereby dub Sir Steve the "Bard of BioCentury."  Read More & Comment...

Waxman Pushes Access to Medicines Over Safety

03/20/2007 07:41 PM |

Henry Waxman supports a bill that would limit the FDA's control over the distribution of pot for medical purposes less than it would limit a doctor's use of new medicines that undergo FDA approval.

Here is the relevant portion of the States Right to Medical Marijuana Act

FEDERAL FOOD, DRUG, AND COSMETIC ACT.

(a) In General- No provision of the Federal Food, Drug, and Cosmetic Act shall prohibit or otherwise restrict--

(1) the prescription or recommendation of marijuana by a physician for medical use,

(2) an individual from obtaining and using marijuana from a prescription or recommendation of marijuana by a physician for medical use by such individual, or

(3) a pharmacy from obtaining and holding marijuana for the prescription or recommendation of marijuana by a physician for medical use,

in a State in which marijuana may be prescribed or recommended by a physician for medical use under applicable State law.

(b) Production- No provision of the Federal Food, Drug, and Cosmetic Act shall prohibit or otherwise restrict an entity established by a State, in which marijuana may be prescribed or recommended by a physician for medical use, for the purpose of producing marijuana for prescription or recommendation by a physician for medical use from producing and distributing marijuana for such purpose.

Compare that to the civil penalties handed out to anyone violating any aspect of any risk management plan doled out by the FDA under Waxman's watchful eye,



Waxman said of those who opposed a bill to give states the right to regulate the use of marijuana for medical purposes: They "think we should just say no to sick and dying patients because it looks like we're getting tough on drugs."

Is that like saying no to sick and dying patients because it looks like we are getting tough on drug safety?

PS. See the following article

High School Students Getting Medical Marijuana Cards In California

Some California teens are giving a new meaning to "high" school.

Students are finding easy access to medical marijuana cards and presenting those cards to school authorities as a legitimate excuse for getting high.
Advertisement


But, where are the cards coming from?

A letter was sent home to parents of students in the Grossmont Union High School District.

"It's not a get out of jail free card at all." Catherine Martin says even though medical marijuana is legal in California, the law doesn't apply to schools which are subject to federal law. The district also says the students most recently suspended for being high with cards in hand - didn't have major illnesses.

"Students are getting them for things like sleeplessness and stress - it just draws into question how easy is it for people to get their hands on these cards."

Well, at least they are not promoting off-label drug use....

http://www.ksdk.com/news/news_article.aspx?storyid=114394  Read More & Comment...

Mark "Subtle Hint" McClellan

03/20/2007 03:21 PM |

Mark McClellan in this week's BioCentury:

"When you have an adverse event reporting system that only captures about 10% of events, that does it with variable time lags, and with inconsistentely collected information, and isn't linked to an adequate infrastructure at the FDA to analyze the information, no wonder there is real public concern."  Read More & Comment...

Anger Management

03/20/2007 10:18 AM |

After reading Daniel Costello's article in the LA Times "Setting a Price for Putting Off Death," I fired off an angry letter to him basically accusing him of favoring rationing and of being heartless.

He called me back and let me have it. I deserved it and he deserved better.

The article is excellent. And it raises an important question about whether our health care system is designed to invest in life or not. More important, I might be upset that some people might think about putting a price on life but I was way out of line.

http://www.latimes.com/business/la-fi-life18mar18,1,2591501.story?page=2&track=rss  Read More & Comment...

Frank and Sense

03/20/2007 09:59 AM |

Frank Burroughs that is, of the Abigail Alliance.

Frank called me yesterday to discuss an article in the March issue of Medical Marketing & Media entitled, "Are NDA Laws Constitutional." He felt that my comments were used to undercut the policy position of the Abigail Alliance.

So I went back to the article and, although I stand by every single one of my quotes, Frank is right in pointing out that the context in which they were used could lead you to think I fundamentally disagree with his position on the issue.

Not so. Not at all. And I feel it's important that I make this point without any ambiguity.

Here is a link to the article:

http://www.mmm-online.com/content/index.php?id=77&no_cache=1&tx_magissue_pi1[pointer]=0&tx_magissue_pi1[showUid]=428

That's good for Frank. And it's good sense.  Read More & Comment...

Congress Forgets About the 5 Million With Alzheimer's

03/20/2007 09:27 AM |

http://news.yahoo.com/s/ap/20070320/ap_on_he_me/alzheimer_s

Latest estimate of people living with Alzheimer's is up to 5 million. Meanwhile as Steve Usdin's excellent piece in Biocentury demonstrates, the FDA Modernization Act of 1997 has done nothing to accelerate the pace of bringing new drugs to people.

Which is why the FDA pushed for Critical Path

Meanwhile Congress ignores the growing Alzheimer problem. Indeed, it seems determined to make it worse. It fiddles with making the FDA decision making process longer and more expensive and so-called medical experts flush with money from junk science litigation about silicone breast implants (defendscience.org) claim that user fees have made more people less safe. (Without any evidence to back it up, but what else is new?) These same people also want follow on biologics to flow like tap water free from the same safety standards they would impose on old medicines.

On a related subject,even if a new drug for Alzheimer's was approved and it cost $10000 a year to stave off onset by 1-3 years, my guess is that the media would question whether medicines that don't cure such a disease are worth it. Don't believe me? Just look at the piece of garbage Daniel Costello of the LA Times wrote about cancer drugs this past Sunday. He basically asked if 3 months of life is worth $40k?

Let him cut short his own life and family to save some cash before he makes that decision for society.

http://www.latimes.com/business/la-fi-life18mar18,1,2591501.story?track=rss
By LAURAN NEERGAARD, AP Medical Writer Tue Mar 20, 6:51 AM ET

WASHINGTON - More than 5 million Americans are living with
Alzheimer's disease, a 10 percent increase since the last Alzheimer's Association estimate five years ago — and a count that supports the long-forecast dementia epidemic as the population grays.



Age is the biggest risk factor, and the report to be released Tuesday shows the nation is on track for skyrocketing Alzheimer's once the baby boomers start turning 65 in 2011. Already, one in eight people 65 and older have the mind-destroying illness, and nearly one in two people over 85.

Unless scientists discover a way to delay Alzheimer's brain attack, some 7.7 million people are expected to have the disease by 2030, the report says. By 2050, that toll could reach 16 million.  Read More & Comment...

Nice but not Necessary

03/20/2007 08:35 AM |

From the current edition of FDA News ...

Experts Question Effect of FDA's New Office of Integrity and Accountability

by Christopher Hollis

FDA Commissioner Andrew von Eschenbach's establishment of a new Office of Integrity and Accountability to address cultural issues within the agency might be a "nice" idea but is not necessary for accomplishing the FDA's mission, according to Peter Pitts, director of the Center for Medicine in the Public Interest (CMPI).

The initiative is just "placating critics on Capitol Hill" and could divert resources away from the FDA's mission, Pitts noted. It is wrong for politics to drive agency policy, Pitts said.

Von Eschenbach announced the creation of the new office during PhRMA's annual board meeting March 15.

However, CMPI Vice President Robert Goldberg said that the creation of the office was a good move for the FDA. "I think what von Eschenbach is trying to do is bring some order to the frat house."

"What he is doing, I think, with this office is giving people who have a grievance or feel that they've been side-stepped an opportunity to . vent and formally present their case to the commissioner, instead of having it fester as some kind of internal squabble within the ranks." That's a smart idea, he added, "and the right thing to do, rather than taking it to Congress where the data and the claims go unfiltered right to the media."

One of the issues the new office will handle is managing conflicts of interest for advisory committee members. Pitts, who dealt with advisory committee issues while serving during the first term of the Bush administration as the FDA's associate commissioner for external relations, noted that restrictive policies regarding conflicts of interest for committees are not conducive to retaining the best and the brightest scientists.

Instead of the best and the brightest, you get "almost the best and kind of the brightest," Pitts said. Goldberg echoed Pitts' sentiment regarding restrictive conflict of interest policies, specifically those set forth by the Institute of Medicine and in S.484, the "Enhancing Drug Safety and Innovation Act of 2007," introduced by Sens. Edward Kennedy (D-Mass.) and
Mike Enzi (R-Wyo.).

"It's ridiculous. People who have won Nobel prizes in pharmacology or medicinal chemistry would have been excluded [as members], both by the recommendations made by the Institute of Medicine and by the standards set forth in [S.484]," Goldberg said.  Read More & Comment...

Buddying Up with the Amigo Society

03/19/2007 03:28 PM |

May I recommend Unlocking Ideas: Essays from the Amigo Society.

Edited by Francesca Ficai; Introduction by Jacob Arfwedson; Arne Björnberg; Manuel Campolini; Pat Cox; Brian Crowley; Duncan Curley; Johan Hjertqvist; Pavel Hrobon; Johnny Munkhammar, Peter Pitts, Jan Remans, Anders Sandberg.

The Amigo Society conferences, held in Brussels, were set up in 2004 to bring together public policy experts, media representatives and members of civil society to debate these and other issues of importance to an enlarged Europe.

Taking concrete examples from all over Europe and North America, this collection examines the broad motivations behind, influences on, and opportunities for future health and welfare policy reform. It also looks to the future – drawing in new fields of policymaking such as biotechnology, tailormade medicines and other technologies expected to drastically alter Europe’s healthcare landscape.

And driving it all, the final set of essays examines consumer empowerment as the major factor which will push forward reform of Europe’s health and welfare systems.

The book can be found at:

http://www.stockholm-network.org/publications/list.php#75

Unlocking Ideas: Essays from the Amigo Society assembles the highlights of these debates over the past two years and provides exciting new insights for the reformers of the future.  Read More & Comment...

SKAPP, rhymes with ...

03/19/2007 01:16 PM |

conflicts.

According to its website -- defendingscience.org -- The Project on Scientific Knowledge and Public Policy examines the nature of science and how it is used and misused in government decision-making and legal proceedings. Through empirical research, conversations among scholars, and publications, SKAPP aims to enhance understanding of how knowledge is generated and interpreted. SKAPP promotes transparent decision-making, based on the best available science, to protect public health.

It receives its funding from the huge settlement awarded by bankrupting Dow Corning during the silicon breast implant litigation.

Can anyone say junk science?

Marcia Angell can and did. She wrote a book called Science on Trial about how science was hijacked by David Kessler and the FDA at the time. Kessler held another advisory committee hearing with non-experts on autoimmune disorders to get the scary results he wanted on about the risks of implants when the first one upheld their safety.

SKAPP just issued an open letter decrying the use of user fees to fund FDA operations.

It was signed by Arnold Relman, husband of Marcia Angell.

It was also signed by a handful of the members of the IOM panel that wrote the drug safety report. So much for objectivity.

It includes Bruce Psaty who has shown David Graham how to twist claims data to scare people. Psaty once claimed that post-menopausal women using calcium channel blockers had a 150 percent increased risk of breast cancer.

But the study was small and, as stated in a National Institutes of Health press release, "the findings do not establish a causal link between calcium channel blocker use and breast cancer." Moreover, the study conflicts with results of SYST-EUR, a recent long-term clinical trial of CCBs that did not reveal any increased cancer incidence.

The Cancer study is just the latest in a series of CCB-scares manufactured by Dr. Curt Furberg of Bowman Gray Medical School -- another co-signed or the letter and oft-time cohort Dr. Bruce Psaty of the University of Washington. Their first scare linked CCBs with increased heart attack risk. But the evidence was so shoddy that Dr. Psaty was forced to apologize to colleagues at the American Society of Hypertension for launching a scare based on a single study with serious limitations.

As for Furberg, he was chair and principal investigator of the ALLHAT trial. He designed the trial. In so doing, he guaranteed that African Americans would be more likely to die during the study comparing different types of blood pressure durings and their impact on heart attack. As Michael Weber, who was on the ALLHAT steering commitee noted: "One factor that drove the ALLHAT conclusions more than anything else was the unexpected 15% higher stroke rate in patients treated with the newer ACE inhibitor drug as compared with the diuretic. But, on close inspection, it turned out that this result was due entirely to a 40% excess stroke rate in black patients. In fact, well before ALLHAT, it was known that blood pressure in African Americans responds poorly to ACE inhibitors, so that the excess stroke rate in these patients was not only predictable, but also highlights the ethical issue of exposing these patients to the high risks of an inappropriate treatment.

Even Furberg has publicly acknowledged that white patients do at least as well on ACE inhibitors as on diuretics, perhaps somewhat better according to an even more recent trial published in the New England Journal of Medicine.

Susan Wood is part of SKAPP and signatory to the letter as well. She was head of the Office of Women's Health at the FDA (She is a PhD, like me, not an MD) Rather than stay and fight for women's reproductive rights at the FDA or help the FDA inform young women about HPV after the launch of the most important vaccine for woman's reproductive health in human history, she left to run SKAPP using money from a slush fund created through questionable science and manipulation of databases.

According to SKAPP

"Major support for SKAPP is provided by the Common Benefit Trust, a fund established pursuant to a court order in the Silicone Gel Breast Implant Products Liability litigation, with additional support from the Alice Hamilton Fund and the Bauman Foundation. The opinions expressed on the DefendingScience website are ours alone. SKAPP's funding is unrestricted. We do not provide our funders advance notice or the opportunity to review or approve the content of this site or any documents produced by the project."

That's fine. I really don't care where they get their dough and it's not an issue as long as they don't make where other people get their money an issue.

The same goes for the editors and producers of new organizations: just serving notice to the media that fails to report any of this but notes that CMPI receives funding from pharma or bio concerns. Transparency cuts both ways.  Read More & Comment...

The Side Effects of Side Effects

03/19/2007 07:42 AM |

Here's an interesting article from Medical Marketing & Media, with many good interviews (Dan Troy, Scott Gottlieb, Steve Galson, Andy von Eschenbach, Dan Carpenter, Sheila Burke, etc.), on the timely question, Wither PDUFA?

Voila la link ...

http://www.mmm-online.com/content/index.php?id=77&no_cache=1&tx_magissue_pi1[sword]=warren%20ross&tx_magissue_pi1[pointer]=0&tx_magissue_pi1[showUid]=422

Worth a look.  Read More & Comment...

Jamie – You sunk my battleship!

03/16/2007 02:43 PM |

At today’s Capitol Hill Sherrod Brown/Jamie Love-in on the joys of compulsory licensing (aka “patent theft”) of pharmaceuticals, the LoveMan showed his true colors.

Jamie said he'd encourage all nations to issue compulsory licenses on all drugs. And when asked why governments like Thailand shouldn’t first try to negotiate with drug companies, he replied that countries couldn't let the drug companies know what they intended to do because they’d “call Karl Rove and, before you know it, battleships are on the way over.”

Jamie Love's true colors? Gun-metal gray and purple haze.  Read More & Comment...

And Dont Forget the Salsa....

03/16/2007 10:48 AM |

Thanks to Stephanie Saul of the NYT for bringing this epidemic of sleep-eating, nacho-munching while driving , to a screeching halt....

http://www.nytimes.com/2007/03/15/business/15drug.ready.html?em&ex=1174190400&en=299f339292b51d83&ei=5087%0A

"The review (of sleep medications) was prompted, in part, by queries to the agency from The New York Times last year, after some users of the most widely prescribed drug, Ambien, started complaining online and to their doctors about unusual reactions ranging from fairly benign sleepwalking episodes to hallucinations, violent outbursts, nocturnal binge eating and — most troubling of all — driving while asleep.

Night eaters said they woke up to find Tostitos and Snickers wrappers in their beds, missing food, kitchen counters overflowing with flour from baking sprees, and even lighted stoves.

Sleep-drivers reported frightening episodes in which they recalled going to bed, but woke up to find they had been arrested roadside in their underwear or nightclothes. The agency said that it was not aware of any deaths caused by sleep-driving.

The reports gained credence from scientific studies. A forensic toxicologist in Wisconsin, Laura J. Liddicoat, gave a presentation at a national meeting on six instances of Ambien-impaired driving.

And Dr. Carlos H. Schenck and Dr. Mark W. Mahowald of the University of Minnesota said that they had been studying cases of nearly 30 Ambien users who developed unusual nighttime eating disorders."

Any info as to whether these people had ingested other meds or alcohol or other substances other than Snickers bars or had an other conditions...? Way to dig Stephanie.  Read More & Comment...

Drugwonks Pop Quiz

03/16/2007 09:22 AM |

Which readily available sedative is associated with the most traffic accidents according to the National Transportation Safety Board:

A. Ambien
B. Benadryl
C. Lunesta
D. Sanjaya Malakar

Anyone who answered D has been watching way too much American Idol. The correct answer is B.

Prescription and OTC medicines that can cause drowsiness include analgesics (pain relievers), antianxiety medication, allergy medicines (antihistamines), blood-sugar medicines, antidepressants, tranquilizers, blood pressure medicines, motion sickness medicines, ulcer medicines, antibiotics, antiseizure medicines, cough syrups and decongestants. According to the National Transportation Safety Board (NTSB), the three most commonly used OTC medications that cause drowsiness are pain relievers, antihistamines and antidepressants.

According to a report published by Vanderbilt University, taking sedating antidepressants even 10 hours before driving is equivalent to driving drunk.  Read More & Comment...

The Good, the Bad, and the Brown.

03/16/2007 08:09 AM |

Some brickbats and bouquets from the March 14 HELP hearing, “Drug User Fees: Enhancing Patient Access and Drug Safety” ...

Bouquets to Senator (Chairman) Kennedy who said the user fee system “demonstrates the failure by Congress to give FDA the funds it needs to do the job that the American public counts on it to do.” And that Congress should “correct this failing, so that FDA does not have to rely excessively on user fees for its basic budget.”

Brickbats to Senator Mikulski who believes there is a “perception that FDA is politicized” because of events like Dr. Susan Wood’s resignation as the Office’s Director, and recent reports that Dr. von Eschenbach intends to cut the Office’s budget by 25%.

And bouquets to Commissioner von E for “clarifying” that reports about a proposed 25% cut in the Office’s budget are “misperceptions.” He stated that he has “no intention to reduce FDA’s commitment to women’s health.”

Bouquets (along with the Dan Troy Prize for First Amendment Sensitivity) to Senator Richard Burr who pointed out that S. 484’s two-year ban on DTC for certain products “will probably not meet a constitutionality test.”

And brickbats to Senator Sherrod Brown who shrugged off the relevance of the US Constitution by commenting that he’s not sure if there are constitutional issues related to limiting DTC advertising.

(Note to Drugwonks readers – we are sure.)

We award our final bouquet to Mark McClellan who pointed out to the committee that that FDA “needs the manpower, technical skills, and technical support to carry out their increasingly complex oversight requirements effectively.” And that “we should aim for nothing less than world class data for evaluating drugs through their lifecycle.”

Amen.

FYI -- Complete witness testimony is available at:

http://help.senate.gov/Hearings/2007_03_14/2007_03_14.html

Enjoy.  Read More & Comment...

The Profit Stigma in Medicine

03/15/2007 04:13 PM |

Meredith Salisbury, is the editor of Genome Technology, the one 'trade' publication everyone must read to learn about the tools and toolmakers that will shape medicine in the 21st century. In the current issue of her publication she has put together the Myths and Misconceptions the people hold about patenting ideas in academia. Most of them comprise the intellectual framework of those that want to drive companies and private investment out of medicine altogether. They are Luddites. As Ms. Salisbury points out concisely and elegantly:

"...More academics follow through on patenting because it can be the fastest and most effective way of getting a research breakthrough to the public. Companies that have to commercialize new technology or other types of discovers want some assurance that they're protected while they're making it ready for market and the first thing they look for is a solid IT position."

For the entire article and to sign up to become a subscriber (you should) go to genome-technology.com  Read More & Comment...

Do Slower Zyprexa Sales = More Untreated Disease?

03/15/2007 01:41 PM |

From Marketwatch.com
http://www.marketwatch.com/news/story/lilly-ceo-zyprexa-2007-seen/story.aspx?guid=%7BF408D59C-9B62-4814-872E-6D94F8186E15%7D

Eli Lilly & Co. Chief Executive Officer Sidney Taurel said Wednesday that because of lingering safety concerns, sales of its blockbuster psychiatric drug Zyprexa in 2007 will largely be flat with 2006 sales.
In an interview with reporters, Taurel said that while Lilly
doesn't anticipate a notable decline in Zyprexa sales, it also doesn't see any substantial growth on the horizon, at least for this year.
"The positioning of the drug is for our sales reps to help physicians identify those patients for whom the efficacy of the drug offsets the potential concern for side effects, and those are, in particular, the urgent patients," said Taurel.
Taurel made his remarks during a meeting of the Boston College Chief Executive's Club in Boston.
Used to treat schizophrenia and bi-polar disorder, Zyprexa has been linked with substantial weight gain in some patients and suspected of triggering diabetes in others.
"They (patients) can use it for awhile, and if they find out there's too much weight gain, they can switch to something else," Taurel continued. "I think the product has found its positioning that way and that's why sales have stabilized."

Except people don't switch to something else. They just stop taking drugs. Period. Or, as with the case when the media fed the SSRI scaremongering, they don't take drugs at all. As with depression, untreated, schizophrenia and manic depression can lead to violence, self-mutilation, substance abuse and suicide.

I am afraid that the slowing sales is a signal of tragedy to come. Lilly has been warning of weight gain and diabetes for years. Coming up with something other than trial and error before starting with meds is what we need to shoot for and is best for all. But others have fanned the flames of fear.  Read More & Comment...

Prescription for Bias

03/15/2007 01:37 PM |

Here's something that should be required reading for all those covering the biotech industry at the WSJ. Think of it as diversity training..

The Business & Media Institute’s new in-depth study Prescription for Bias,” which documents unbalanced media coverage of the pharmaceutical industry. Released today, the report quantifies the bias against drug companies based on analysis of 132 stories on prescription or over-the-counter drugs from the ABC, CBS and NBC evening newscasts between January 1 and Sept. 30, 2006.


Among the study’s key findings:


· Industry Ignored – 80% of stories excluded the viewpoint of the pharmaceutical industry

· Cost to Consumer – Media overemphasized consumer drug costs as opposed to drug development costs at a radio of 11:1

· Companies Unnoticed – Only 22% of the stories even named the company responsible for developing life saving cures

· What Development Costs? – A mere 2% of the stories addressed the cost to companies for researching and developing drugs


The report also includes recommendations to improve network coverage.


The full report can be found at:



http://www.businessandmedia.org/specialreports/2007/PrescriptionForBias/PrescriptionForBias_execsum.asp



Oddly enough, a story that aired on all networks last night was consistent with many of the reports findings. When reporting on the new breakthrough drug Tykerb, the media failed to give due credit to GlaxoSmithKline or report the development costs. You can read about it here:



http://www.businessandmedia.org/articles/2007/20070314165615.aspx  Read More & Comment...